This approach has proven efficacious in preclinical models, with depletion of the murine CD163+ Tim4+ TRM subset via anti-CD163 mAb-coated cytotoxic liposomes found to reduce ovarian tumour burden in mice [55]. This evidence concerns the gene CD163 and ovarian neoplasm.